Intellia Therapeutics Inc’s recently made public that its Director CHASE WILLIAM J acquired Company’s shares for reported $1.0 million on Aug 20 ’25. In the deal valued at $10.03 per share,100,000 shares were bought. As a result of this transaction, CHASE WILLIAM J now holds 134,693 shares worth roughly $1.53 million.
Then, Dulac Edward J III sold 7,462 shares, generating $104,617 in total proceeds. Upon selling the shares at $14.02, the EVP, Chief Financial Officer now owns 106,062 shares.
Before that, Clark Eliana sold 1,022 shares. Intellia Therapeutics Inc shares valued at $10,036 were divested by the EVP, Chief Technical Officer at a price of $9.82 per share. As a result of the transaction, Clark Eliana now holds 95,369 shares, worth roughly $1.09 million.
Wolfe Research upgraded its Intellia Therapeutics Inc [NTLA] rating to an Outperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. JP Morgan also remained covering NTLA and has decreased its forecast on February 28, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on February 28, 2025. It rated NTLA as “a Sell” which previously was an “a Neutral”.
Price Performance Review of NTLA
On Monday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock jump 8.17% to $11.38. Over the last five days, the stock has gained 6.06%. Intellia Therapeutics Inc shares have fallen nearly -51.80% since the year began. Nevertheless, the stocks have fallen -2.40% over the past one year. While a 52-week high of $24.16 was reached on 07/23/25, a 52-week low of $5.90 was recorded on 04/07/25.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 11.02, which if violated will result in even more drops to 10.65. On the upside, there is a resistance level at 11.65. A further resistance level may holdings at 11.91.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-07-31, dropping by -0.42 million shares to a total of 29.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 30.13 million shares. There was a decline of -1.42%, which implies that there is a negative sentiment for the stock.
